Improving the Working Models for Drug–Drug Interactions: Impact on Preclinical and Clinical Drug Development
Pharmaceutics · 24.01.2025 · 17 (2) · 159
DOI: 10.3390/pharmaceutics17020159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 24.01.2025. Verfasst von James Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim Pharmaceuticals, Inc..
Abstract (Originalsprache)
Background
Pharmacokinetic drug–drug interactions (DDIs) can be caused by the effect of a pharmaceutical compound on the activity of one or more subtypes of the Cytochrome P450 (CYP) family, UDP-glucuronosyltransferases (UGTs), and/or transporters. As the number of therapeutic areas with polypharmacy has increased, interest has grown in assessing the risk of DDIs during the early phases of drug development. Various lines of research have led to improved mathematical models to predict DDIs, culminating in the Food and Drug Administration’s (FDA) guidelines on evaluating pharmacokinetic DDI risks. However, the recommended static models are highly conservative and often result in false positive predictions. The current research aims to improve the workflow for assessing CYP-mediated DDI risk using Boehringer Ingelheim (BI) proprietary compounds.
Methods
The Drug–drug Interaction Risk Calculator (PharmaPendium) was used to evaluate the mechanistic static model, and predictions were correlated with human pharmacokinetic studies from Phase I clinical trials.
Results
The results demonstrated that the FDA formula performed well in predicting DDIs for BI proprietary compounds. Furthermore, the integration of either human renal excretion or preclinical species total excretion data into the mechanistic static model enhanced the predictive performance for candidate drugs as victims in DDIs.
Conclusions
The basic static models (BSMs) for drug interactions should be used in early drug discovery to “rule out” DDI risks because of the minimal inputs required and the low rate of false negative predictions. Mechanistic static models (MSMs) can then be implemented for compounds that require additional evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
- College of Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA.
- School of Pharmacy, University of Washington, Seattle, WA 98195, USA.
- College of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
- Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach an der Riß, Germany.
ORCID-Profile: Beshoy Armanios, Peter Stopfer, Fenglei Huang
Förderung
- Boehringer Ingelheim Pharmaceuticals, Inc.
Zitieren
APA
Nguyen, J., Joseph, D., Chen, X., Armanios, B., Sharma, A., Stopfer, P., & Huang, F. (2025). Improving the Working Models for Drug–Drug Interactions: Impact on Preclinical and Clinical Drug Development. Pharmaceutics, 17(2), 159. https://doi.org/10.3390/pharmaceutics17020159
Vancouver
Nguyen J, Joseph D, Chen X, Armanios B, Sharma A, Stopfer P, et al. Improving the Working Models for Drug–Drug Interactions: Impact on Preclinical and Clinical Drug Development. Pharmaceutics. 2025;17(2):159. doi:10.3390/pharmaceutics17020159
BibTeX
@article{Nguyen2025,
author = {Nguyen, James and Joseph, David and Chen, Xin and Armanios, Beshoy and Sharma, Ashish and Stopfer, Peter and Huang, Fenglei},
title = {Improving the Working Models for Drug–Drug Interactions: Impact on Preclinical and Clinical Drug Development},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {159},
doi = {10.3390/pharmaceutics17020159}
}
EUVIMED